Horizon, Abcam Sign License and Supply Agreement
News Sep 09, 2015
The agreement will initially see Abcam have exclusive access to over 1,800 human diploid and haploid cell line models from Horizon’s X-MAN® collection, which will aid the functional validation of Abcam’s existing monoclonal and polyclonal antibodies marketed to the global research community. Horizon will also develop additional haploid cell lines to validate new antibodies introduced by Abcam.
The data generated by Abcam will also add value to Horizon’s cell line collection by providing independent evidence that the cell lines demonstrate the desired functional output of gene editing and providing time and cost savings for the company’s cell line manufacturing process. The new cell lines generated for Abcam will be available to customers across all of Horizon’s core products and services.
Under the terms of the agreement, Horizon will receive exclusivity payments totaling £660,000 (c$1,000,000) across an initial three year term, with a further £1,275,000 (c$1,950,000) across years four to six if Abcam extends the exclusivity period. For any additional haploid cell lines developed, preferred pricing will be charged. In addition, Horizon will receive a royalty on the sale of Abcam antibodies marketed using validation data derived from Horizon cell lines for a period of 10 years from the first date of sale.
Beyond the initial term of the agreement there is scope to extend the collaboration to cover the complete human proteome (17,000+ targets), and the potential to co-develop novel functional genomics products and services with Abcam.
Dr. Paul Morrill, President, Products, Horizon Discovery Group, commented: “This agreement represents significant progress for Horizon in creating new and scalable channels to market for its cell line products. Abcam’s choice of Horizon’s cell lines to support the development and quality control for their antibody catalog further validates the value that our cell lines can provide in a variety of applications. We believe that this agreement represents the first step in building a long term relationship with a true world-leader in the research antibody field.”
Alan Hirzel, CEO, Abcam, said: “We always strive to provide the highest quality product and relevant supporting data. Our decision to validate antibodies with these Horizon knockout cell lines means we can give researchers an enhanced level of confidence that they are using the highest specificity products. We look forward to working with Horizon to bring the benefits of this innovation to serve life science research globally.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018